Oligomerix Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$500K
- Investors
-
5
Oligomerix General Information
Description
Developer of small molecule therapeutics designed to treat Alzheimer's disease with an upstream approach. The company specializes in disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein, ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia, enabling physicians to treat their patients in an enhanced way.
Contact Information
Website
www.oligomerix.comCorporate Office
- 1300 Morris Park Avenue
- Room 1211
- Bronx, NY 10461
- United States
Corporate Office
- 1300 Morris Park Avenue
- Room 1211
- Bronx, NY 10461
- United States
Oligomerix Timeline
Oligomerix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Grant | 18-Nov-2025 | $500K | Completed | Clinical Trials - Phase 2 | ||
| 15. Later Stage VC | 06-Dec-2024 | Completed | Clinical Trials - Phase 2 | |||
| 14. Grant | 04-Oct-2022 | Completed | Clinical Trials - Phase 1 | |||
| 13. Later Stage VC (Series B) | 29-Mar-2022 | Completed | Clinical Trials - Phase 1 | |||
| 12. Grant | 01-Jan-2020 | Completed | Clinical Trials - Phase 1 | |||
| 11. Grant | 07-Sep-2017 | Completed | Clinical Trials - Phase 1 | |||
| 10. Grant | 02-May-2016 | Completed | Clinical Trials - Phase 1 | |||
| 9. Grant | 01-May-2016 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC (Series B) | 15-Apr-2015 | $400K | $5.2M | Completed | Clinical Trials - Phase 1 | |
| 7. Grant | 11-Sep-2013 | $1.7M | $4.8M | Completed | Clinical Trials - Phase 1 |
Oligomerix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Oligomerix Comparisons
Industry
Financing
Details
Oligomerix Competitors (23)
One of Oligomerix’s 23 competitors is CuraSen, a Venture Capital-Backed company based in San Carlos, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CuraSen | Venture Capital-Backed | San Carlos, CA | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Fauna Bio | Venture Capital-Backed | Emeryville, CA | ||||
| Cerecin | Venture Capital-Backed | Broomfield, CO | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA |
Oligomerix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Oligomerix Patents
Oligomerix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240158357-A1 | Novel quinazolinones that inhibit the formation of tau oligomers and their method of use | Inactive | 19-Jun-2019 | ||
| US-11306075-B2 | Benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use | Inactive | 20-Dec-2016 | ||
| US-12331043-B2 | Benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use | Active | 20-Dec-2016 | ||
| ES-2953474-T3 | New quinazolinones that inhibit the formation of tau oligomers and their use | Active | 20-Dec-2016 | ||
| JP-2023052610-A | Novel benzofuran, benzothiophene and indole analogues that inhibit the formation of tau oligomers and methods of their use | Active | 20-Dec-2016 | C07D409/14 |
Oligomerix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Oligomerix Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Counterview Capital | Venture Capital | Minority | ||
| National Institute on Aging | Government | |||
| Durand Venture Associates | Venture Capital | Minority | ||
| Wheatley Partners | PE/Buyout | Minority | ||
| Alzheimers Drug Discovery Foundation | Not-For-Profit Venture Capital |
Oligomerix FAQs
-
When was Oligomerix founded?
Oligomerix was founded in 2006.
-
Where is Oligomerix headquartered?
Oligomerix is headquartered in Bronx, NY.
-
What is the size of Oligomerix?
Oligomerix has 11 total employees.
-
What industry is Oligomerix in?
Oligomerix’s primary industry is Drug Discovery.
-
Is Oligomerix a private or public company?
Oligomerix is a Private company.
-
What is Oligomerix’s current revenue?
The current revenue for Oligomerix is .
-
How much funding has Oligomerix raised over time?
Oligomerix has raised $7.72M.
-
Who are Oligomerix’s investors?
Counterview Capital, National Institute on Aging, Durand Venture Associates, Wheatley Partners, and Alzheimers Drug Discovery Foundation have invested in Oligomerix.
-
Who are Oligomerix’s competitors?
CuraSen, Alzheon, Fauna Bio, Cerecin, and Capricor Therapeutics are some of the 23 competitors of Oligomerix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
